Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

“ (Weight loss medications) can help, for sure, but exercise and getting enough protein to make sure you aren’t losing muscle ...

Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Men, baby boomers, and postgraduate-degree holders were among those most likely to say they wouldn’t choose medication over ...

The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...

All of this means Lilly investors shouldn't panic. Even in the "worst case," Lilly's weight loss drugs have driven major revenue growth, and this is likely to continue -- whether compounders halt ...